MONTREAL–Results from the largest real-world propensity-matched comparison to date show that radial-to-peripheral (R2P) access achieves procedural success rates comparable to traditional common femoral artery (CFA) access for lower extremity peripheral artery disease (PAD) revascularization. However, six-month major adverse limb events (MALE) were higher in the R2P group, predominantly driven by target vessel revascularization (TVR). Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal. 

In 2021, the ACC/AHA/SCAI Coronary Artery Revascularization Guidelines designated radial artery access, a minimally invasive approach in which physicians perform procedures through the radial artery in the wrist, a Class I, Level A recommendation for patients undergoing coronary percutaneous coronary intervention (PCI) to reduce bleeding and vascular complications, reflecting strong clinical evidence supporting the approach. Despite radial access becoming common for coronary procedures, most interventions for PAD are still performed through the common femoral artery in the groin. To date, clinical evidence supporting transradial access in peripheral arterial interventions has been largely limited to single-arm and observational studies.

In this retrospective study, researchers utilized data from the multicenter, core laboratory-adjudicated XLPAD registry (2023-2024, NCT01904851) to propensity match consecutive R2P procedures to CFA cases, adjusting for demographics, cardiovascular risk, and clinical presentation. The primary endpoint was MALE, a composite of all-cause mortality, TVR, and major amputations at six months. Among the 546 patients included in the study, nearly half of the lesions were chronic total occlusions, and mean lesion length was greater in the CFA group. In addition, the use of stents (56%) and drug-coated balloons (29%) was similar in both groups.

Using a multivariable Cox proportional hazards model, the study found procedural success was higher in the CFA group compared to the R2P group (95% vs. 87%, respectively) but remained clinically non-inferior (p=0.001; prespecified margin 15%). At six months, the R2P group had a higher incidence of MALE (15.8% vs. 8.1%; HR 1.99, 95% CI 1.19-3.35; p=0.006), mainly due to TVR (11.7% vs. 5.1%; p=0.006). Rates of death (3.3%) and major amputation (1.1%) were similar between the two groups.

“With proper training, experience, and the right equipment, many patients can be safely and effectively treated by a transradial approach to treat their PAD,” said Sameh Sayfo, MD, MBA, FSCAI, interventional cardiologist at Baylor Scott & White The Heart Hospital in Plano, Texas. “In addition to procedural safety, this approach shortens hospital stays and makes bleeding complications easier to manage. Continued research and device innovation will be important to advance the technique further. We hope these findings help inform future randomized trials and ultimately contribute to meaningful changes in clinical guidelines for peripheral arterial interventions.” 

Researchers noted that extended follow-up analyses are ongoing, with additional substudies planned to further evaluate outcomes.
 
Session Details:

• “6-Month Outcomes of the CARPOOL Study: Radial-to-Peripheral Versus Femoral Access in Lower Extremity PAD Revascularization”
  • Friday, April 24; 3:57-4:05 PM ET
  • Palais des Congrès de Montréal, 510b (5th Level)

Media Contact

Gavin Stern 

[email protected], 202-644-8561 

About SCAI 2026 Scientific Sessions

The SCAI Scientific Sessions annual meeting convenes nearly 2,000 of the world’s premier clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. With 500+ faculty and hundreds of abstracts, experts in the field work together to share the latest clinical data, procedural guidance, and advanced expertise. Highlights include live cases, featured clinical research, new SCAI clinical documents, case-based learning, and keynote speakers. For more information, visit SCAI 2026 Scientific Sessions & CAIC-ACCI Summit.

About the Society for Cardiovascular Angiography & Interventions (SCAI) 

The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 5,000 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease.  For more information, visit www.scai.org.

About Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI)

The Canadian Association of Interventional Cardiology / Association Canadienne de cardiologie d’intervention (CAIC-ACCI) is a national body representing 307 interventional cardiologists across Canada. Dedicated to advancing excellence in cardiovascular care, CAIC-ACCI plays a central role in supporting its members through high-quality educational events, fostering professional growth, and promoting innovation in clinical practice. The organization is also deeply committed to the training and development of interventional cardiology Fellows, helping to shape the next generation of specialists. For more information, visit www.caic-acci.org.